(19)
(11) EP 2 678 327 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.09.2016 Bulletin 2016/39

(45) Mention of the grant of the patent:
17.08.2016 Bulletin 2016/33

(21) Application number: 12709965.3

(22) Date of filing: 22.02.2012
(51) International Patent Classification (IPC): 
C07D 333/22(2006.01)
A61K 31/381(2006.01)
 C07D 409/04(2006.01)
A61P 25/28(2006.01)
(86) International application number:
PCT/IB2012/050806
(87) International publication number:
WO 2012/114285 (30.08.2012 Gazette 2012/35)

(54)

HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS

HETEROARYLDERIVATE ALS ALPHA7-NACHR-MODULATOREN

DÉRIVÉS HÉTÉROARYLE À TITRE DE MODULATEURS DES NACHR ALPHA 7

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 23.02.2011 IN KO02422011
09.09.2011 IN KO11842011

(43) Date of publication of application:
01.01.2014 Bulletin 2014/01

(73) Proprietor: Lupin Limited
Mumbai 400055 (IN)

(72) Inventors:
  • SINHA, Neelima
    Pune 411 042 (IN)
  • JANA, Gourhari
    Pune 411 042 (IN)
  • SACHCHIDANAND, Sachchidanand
    Pune 411 042 (IN)
  • KURHADE, Sanjay, Pralhad
    Pune 411 042 (IN)
  • KARCHE, Navnath, Popat
    Pune 411 042 (IN)
  • HAJARE, Anil, Kashiram
    Pune 411 042 (IN)
  • TILEKAR, Ajay, Ramchandra
    Pune 411 042 (IN)
  • PALLE, Venkata, P.
    Pune 411 042 (IN)
  • KAMBOJ, Rajender, Kumar
    Pune 411 042 (IN)

(74) Representative: Watson, Robert James et al
Mewburn Ellis LLP
City Tower 40 Basinghall Street London EC2V 5DE
City Tower 40 Basinghall Street London EC2V 5DE (GB)


(56) References cited: : 
WO-A1-2008/002974
   
  • TATSUMI ET AL.: "(+)-3-[2-(benzo[b]thiophen-2-yl)-2-oxoeth yl]-1-azabicyclo[2.2.2]oct ane as potent agonists for the alpha-7 nicotinic acetylcholine receptor", BIOORG. MED. CHEM. LETT., vol. 14, no. 14, 1 January 2004 (2004-01-01), pages 3781-3784, XP002327499, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2004.04.091
  • TATSUMI ET AL.: "(R)-3'-(3-Methylbenzo(b)thiophen-5-yl)- spiro(1-azabicyclo(2,2,2)octa ne-3,5'- oxazolidin)-2'-one, a Novel and Potent alpha7 Nicotinic Acetylcholine Receptor Partial Agonist Displays Cognitive Enhancing Properties", J. MED. CHEM., vol. 49, no. 14, 1 January 2006 (2006-01-01), pages 4374-4383, XP002538696, ISSN: 0022-2623, DOI: 10.1021/JM060249C [retrieved on 2006-06-16]
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).